Mirati is seeking collaboration opportunities for novel oncology assets targeting kinase inhibitors and epigenetic targets. Mirati is also seeking collaborations with investigators and clinical sites interested in exploring program combinations and novel approaches to targeted cancer therapy.

Currently, worldwide rights to all pipeline programs are owned by Mirati Therapeutics except certain Asian rights for sitravatinib, where the program is partnered with BeiGene.


Please contact bd@mirati.com